Sep 1, 2015 · The study was based on 250 patients between the ages of 18 and 80 years with NYHA class II-IV chronic HF of either ischemic or non-ischemic etiology and a left ventricular …

Sep 24, 2013 · In HF, the level and the activity of sarcoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) is decreased, contributing directly to impaired cardiac contraction and relaxation.

Patients enrolled in CUPID 2 were between the ages of 18 and 80 years, had a diagnosis of NYHA class II-IV chronic HF of either ischemic or non-ischemic etiology and a left ventricular …

Jun 27, 2011 · The phase 2 Calcium Upregulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) trial is a randomized, double-blind, placebo-controlled, …

CUPID 2 is a phase 2b, double-blind, placebo-controlled, multinational, multicenter, randomized event-driven study in up to 250 patients with moderate-to-severe heart failure with reduced …

The CUPID 2 (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) trial is designed to evaluate whether increasing SERCA2a activity …

AAV1/SERCA2a continues to demonstrate an excellent safety profile and substantially improved clinical outcomes compared to optimal medical therapy (placebo) in advanced HF patients at 9 …

Nov 23, 2010 · Background: CUPID (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) is a phase 2 study which compared AAV1/SERCA2a …

The AGENT-HF (NCT01966887) trial investigated the impact of adeno-associated virus (AAV1)/SERCA2a on ventricular remodelling using multimodality non-invasive cardiac imaging.

CUPID The CUPID trial 2 was a Phase 2 blinded, randomized, placebo-controlled, multicenter study examining the effects of AAV1. SERCA2a in 39 subjects with stable symptomatic HFrEF …